

MEDIA RELEASE

Listing Update

Sydney, Australia 30 October 2020 – the directors of Azure Health Technology Limited (**AZT**), have been exploring options for raising capital to fund the advancement of the Company's drug development and nutraceuticals programs as well maximising the value and liquidity of the Company's shares via a listing on a major stock exchange.

As part of the above process, an Application for In-Principle Advice in relation to a proposed Initial Public Offering was submitted to the Australian Securities Exchange (**ASX**). The directors have been advised by AZT's legal counsel (who has in turn been verbally advised by the ASX) that there is a significant likelihood that ASX would decline a Listing Application from AZT. Therefore AZT will not be lodging a Listing Application with ASX.

A number of options are being assessed and the directors expect to be able to provide a further update with more detail shortly.

This announcement has been approved for release by the Board of Azure Health Technology Limited.

For more information please contact:

Dr Glenn Tong
CEO and Managing Director
Tel: +61 (0) 412 193 350

Ms Catriona Glover
Company Secretary
Tel: +61 (0) 402 328 200

Mr Warrick Lace
Investor Relations
Reach Corporate Pty Ltd
+61 (0) 404 656 408

About Azure Health Technology Limited

Azure Health Technology Limited (AZT) is an Australian public unlisted biotechnology company developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia, hypertension and diabetes. AZT owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines. For more information see: www.azureht.com.au
